Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea

Metabolism: Clinical and Experimental

Volumn 55, Issue 8, 2006, Pages 1107-1112

  Kim, Chul Sik ^a   Nam, Jae Hyun ^a   Nam, Ji Sun ^a   Park, Jong Suk ^a   Kang, Eun Seok ^a   Ahn, Chul Woo ^a   Cha, Bong Soo ^a   Lim, Sung Kil ^a   Kim, Kyung Rae ^a   Lee, Hyun Chul ^a   Huh, Kap Bum ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; AUTOANTIBODIES; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KOREA; MALE; MIDDLE AGED;

EID: 33745826667     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.04.006     Document Type: Article

References (35)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
2. Zimmet P.Z., Tuomi T., Mackay I.R., Rowley M.J., Cohen M., and Lang D.A. Latent autoimmune diabetes in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11 (1994) 299-303
3. Kasuga A., Ozawa Y., Maruyama T., Ishihara T., Amemiya S., and Saruta T. Autoantibody against ICA512 did not improve test sensitivity for slowly progressive IDDM in adults. Diabetes Care 20 (1997) 679-680
4. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay J.R., et al. UK Prospective Diabetes Study Group: UKPDS 25: antibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350 (1997) 1288-1293
5. Petersen J.S., Hejnaes K.R., Moody A., Karlsen A.E., Marshall M.O., Hoier-Madsen M., et al. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43 (1994) 459-467
6. Schmidli R.S., DeAizpurua H.J., Harrison L.C., and Colman P.G. Antibodies to glutamic acid decarboxylase in at-risk and clinical insulin-dependent diabetic subjects: relationship to age, sex and islet cell antibody status, and temporal profile. J Autoimmun 7 (1994) 55-66
7. Christie M.R., Daneman D., Champagne P., and Delovitch T.L. Persistence of serum antibodies to 64,000-Mr islet cell protein after onset of type I diabetes. Diabetes 39 (1990) 653-656
8. Park Y., Lee H., Koh C.S., Min H., Rowley M., Mackay I.R., et al. The low prevalence of immunogenetic markers in Korean adult-onset IDDM patients. Diabetes Care 19 (1996) 241-245
9. Thai A.C., Ng W.Y., Loke K.Y., Lee W.R., Lui K.F., and Cheah J.S. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. Diabetologia 40 (1997) 1425-1430
10. Damanhouri L.H., Dromey J.A., Christie M.R., Nasrat H.A., Ardawi M.S., Robins R.A., et al. Autoantibodies to GAD and IA-2 in Saudi Arabian diabetic patients. Diabet Med 22 (2005) 448-452
11. Takeda H., Kawasaki E., Shimizu I., Konoue E., Fujiyama M., Murao S., et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25 (2002) 995-1001
12. Abiru N., Takino H., Yano M., Kawasaki E., Yamasaki H., Yamaguchi Y., et al. Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J Autoimmun 9 (1996) 683-688
13. Bruno G., Salvia A.D., Arcari R., Borra M., Grosso N., Carta Q., et al. The Piedmont Study Group for Diabetes Epidemiology: clinical, immunological, and genetic heterogeneity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30-54 years. Diabetes Care 22 (1999) 50-55
14. Inukai T., Fujiwara Y., Tayama K., Aso Y., Ogino K., and Takemura Y. Clinical characteristics of patients with the initial diagnosis of NIDDM with positivity for antibodies to glutamic acid decarboxylase. Exp Clin Endocrinol Diabetes 105 (1997) 327-330
15. Tuomi T., Carlsson Å., Li H., Isomaa B., Miettinen A., Nilsson A., et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48 (1999) 150-157
16. Gambelunghe G., Forini F., Laureti S., Murdolo G., Toraldo G., Santeusanio F., et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol 52 (2000) 565-573
17. Pietropaolo M., Barinas-Mitchell E., Pietropaolo S.L., Kuller L.H., and Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 49 (2000) 32-38
18. Fukui M., Nakamura N., Nakano K., Aoji O., Obayashi H., Shigeta H., et al. Antibodies to GAD in elderly patients with previously diagnosed NIDDM. Diabetes Care 21 (1998) 675-681
19. Niskanen L.K., Tuomi T., Karjalainen J., Groop L.C., and Unsitupa M.I.J. GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes Care 12 (1995) 1557-1565
20. Zinman B., Kahn S.E., Haffner S.M., O'Neill M.C., Heise M.A., and Freed M.I. ADOPT Study Group: phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53 (2004) 3193-3200
21. Juneja R., Hirsch I.B., Naik R.G., Brooks-Worrell B.M., Greenbaum C.J., and Palmer J.P. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 50 (2001) 1008-1013
22. Rattarasarn C., Aguilar Diosdado M., and Soonthornpun S. Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand. Diabetes Res Clin Pr 37 (1997) 193-197
23. Fukui M., Nakano K., Maruya E., Saji H., Ohta K., Ohta M., et al. Diagnostic significance of antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary oral hypoglycemic agents failure. Clin Immunol 85 (1997) 182-186
24. Ko K.W., Yang S.W., and Cho N.H. The incidence of IDDM in Seoul from 1985 to 1988. Diabetes Care 17 (1994) 1473-1475
25. Min H.K. Non-insulin-dependent diabetes mellitus (NIDDM) in Korea. Diabet Med 13 (1996) S13-S15
26. Schmidli R.S., Colman P.G., and Bonifacio E. Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes 44 (1995) 636-640
27. Bingley P.J., Bonifacio E., and Mueller P.W. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52 (2003) 1128-1136
28. Ko K.S., Hong S.K., Lee K.U., Kim N.H., Choi D.S., Ihm S.H., et al. The Frequency of ICA and anti-GAD Antibody in Korean IDDM and NIDDM Patients. J Kor Diabetes Asso 22 (1998) 312-319
29. Roll U., Nuber A., Schroder A., Gerlach E., Janka H.U., and Ziegler A.G. No association of antibodies to glutamic acid decarboxylase and diabetic complications in patients with IDDM. Diabetes Care 18 (1995) 210-215
30. Ladin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958 (2002) 112-116
31. Torn C., Landin-Olsson M., Lernmark A., Schersten B., Ostman J., Arnqvist H.J., et al. Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33 (2001) 115-120
32. Hamaguchi K., Kimura A., Kusuda Y., Yamashita T., Yasunami M., Takahasi M., et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res Clin Pract 66 (2004) 163-171
33. Leslie R.D.G. Intervention in patients with type 1 diabetes masquerading as type 2. Diabetes Nutr Metab 9 (1996) 319-324
34. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual B-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 128 (1998) 517-523
35. Isomaa B., Almgren P., Henricsson M., Taskinen M.R., Tuomi T., Groop L., et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 22 (1999) 1347-1353